TREATMENT OUTCOMES OF NEOADJUVANT CHEMOTHERAPY WITH AC-T REGIMEN IN STAGE II, III BREAST CANCER AT K HOSPITAL AND TUYEN QUANG GENERAL HOSPITAL

Thị Oanh Trần1,2, , Văn Tú Đào2,3
1 Bệnh viện Đa khoa tỉnh Tuyên Quang
2 Trường Đại học Y Hà Nội
3 Bệnh viện K

Main Article Content

Abstract

Background: Neoadjuvant chemotherapy with the AC-T regimen plays a core role in the treatment of stage II and III breast cancer (BC) to reduce tumor size, increase surgical resectability, and eradicate micrometastases. This study aimed to: (1) Describe the clinical and subclinical characteristics of BC patients treated with AC-T at K Hospital and Tuyen Quang General Hospital; (2) Evaluate the response and toxicities of the regimen.


Methods: A retrospective, matched-pair analytical descriptive study was conducted on 84 stage II and III BC patients receiving neoadjuvant 4AC-4T chemotherapy (every 3 weeks or dose-dense every 2 weeks) at Tuyen Quang Provincial General Hospital (n = 28) and K Hospital (n = 56, matched at a 1:2 ratio) from January 2022 to January 2026. Clinical response was evaluated according to RECIST 1.1, pathological complete response (pCR) according to the Chevallier classification, and toxicity according to WHO/CTCAE criteria.


Results: The mean age was 53.9 ± 10.1 years; stage III accounted for 70.2%. Invasive ductal carcinoma accounted for 86.9%; ER/PR(+) was 73.8%. The overall clinical response rate was 97.6% (complete response, 41.7%). 100% of patients underwent successful surgery. The pCR rate was 47.6% (K Hospital 48.2% vs. Tuyen Quang 46.4%, p > 0.05). Patients with tumors ≤ 5 cm achieved a significantly higher pCR rate than those with tumors > 5 cm (52.9% vs. 21.4%, p = 0.031). Grade 3–4 leukopenia occurred in 21.5% of patients. Non-hematological toxicities were predominantly grade 1–2.


Conclusions: Neoadjuvant 4AC-4T chemotherapy yields high clinical response and pathological complete response (pCR) rates in stage II and III breast cancer patients at both the central level (K Hospital) and the provincial level (Tuyen Quang Provincial General Hospital), with good tolerability and safely manageable toxicities.

Article Details

References

1. Phạm Tuấn Anh. Đánh giá tính an toàn của phác đồ 4AC-4P liều dày trong điều trị bổ trợ ung thư vú. Tạp chí Y học Việt Nam. 2019;482(2):45-50.
2. Lê Thanh Đức. Nghiên cứu hiệu quả hóa trị bổ trợ trước phẫu thuật phác đồ AP trong ung thư vú giai đoạn III. Tạp chí Y học Việt Nam. 2014;418(1):112-118
3. Phùng Thị Huyền, Trần Văn Thuấn. Đặc điểm lâm sàng, mô bệnh học bệnh nhân ung thư vú có bộ ba thụ thể âm tính ER(-), PR(-), HER2(-) giai đoạn 2005-2007 tại Bệnh viện K. Tạp chí Y học Việt Nam. 2012;390(1):15-18
4. Hà Thành Kiên. Đánh giá đáp ứng hóa chất bổ trợ trước 4AC-4T liều dày trong điều trị ung thư vú. Tạp chí Ung học Việt Nam. 2018;6(2):88-94.
5. Nguyễn Thị Thủy. Đánh giá kết quả hóa trị bổ trợ trước phác đồ 4AC-4T trên bệnh nhân ung thư vú giai đoạn III. Tạp chí Y học Lâm sàng. 2016;92:34-40
6. Bear HD, Anderson S, Smith RE, et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2006;24(13):2019-2027.
7. Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. The Lancet. 2014;384(9938):164-172.
8. Rastogi P, Anderson SJ, Bear HD, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol. 2008;26(5):778-785.